Clinical Research Directory
Browse clinical research sites, groups, and studies.
Summary
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
Official title: A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2023-07-19
Completion Date
2025-07-31
Last Updated
2025-01-14
Healthy Volunteers
No
Conditions
Interventions
Asciminib
There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
Locations (14)
Novartis Investigative Site
Wŏnju, Gangwon-do, South Korea
Novartis Investigative Site
Uijeongbu-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea
Novartis Investigative Site
Seoul, Seocho Gu, South Korea
Novartis Investigative Site
Incheon, South Korea
Novartis Investigative Site
Jeollanam, South Korea
Novartis Investigative Site
Pusan, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Taegu, South Korea